Trimel to Report Second Quarter 2013 Results and Host Investor Call

(firmenpresse) - TORONTO, ONTARIO -- (Marketwired) -- 07/25/13 -- Trimel Pharmaceuticals Corporation (TSX: TRL) will report its second quarter financial results for the period ended June 30, 2013 on Wednesday, July 31, 2013 after the market closes.

Management of the Company will host a conference call to discuss these results and update investors on the status of its business on Thursday, August 1, 2013, at 8:30 a.m. Eastern Daylight Time.

To access the call live, please dial 416-340-2216 (Toronto), 1-866-226-1792 (Canada and U.S.) or 00-800-9559-6849 (International). Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays.

A replay of the conference call will be available until 7:00 p.m. Eastern Daylight Time on Thursday, August 8, 2013 by dialing 905-694-9451 (Toronto), 1-800-408-3053 (Canada and U.S.) or 00-800-3366-3052 (International), using access code: 3086288#.

For further information regarding Trimel Pharmaceuticals Corporation, please contact Kenneth Howling, Chief Financial Officer at (416) 679-0536 or via email at .

About Trimel

Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. A New Drug Application for CompleoTRT™, a product using Trimel's licensed bioadhesive intranasal technology, has been accepted for review by the FDA for regulatory approval in the United States. For more information, please visit



Contacts:
Trimel Pharmaceuticals Corporation
Kenneth G. Howling
Chief Financial Officer
416 679 0536

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: Marketwired
Datum: 25.07.2013 - 21:00 Uhr
Sprache: Deutsch
News-ID 282013
Anzahl Zeichen: 0

contact information:
Town:

TORONTO, ONTARIO

Kategorie:

Healthcare

Diese Pressemitteilung wurde bisher 233 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Trimel to Report Second Quarter 2013 Results and Host Investor Call"
steht unter der journalistisch-redaktionellen Verantwortung von

Trimel Pharmaceuticals Corporation (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Trimel Announces Filing of NATESTO(TM) With Health Canada ...

TORONTO, ONTARIO -- (Marketwired) -- 01/26/15 -- Trimel Pharmaceuticals Corporation (TSX: TRL) today announced that it has filed a New Drug Submission with Health Canada for NATESTO™ (testosterone) nasal gel for replacement therapy in men for cond ...

Trimel Announces Closing of Exclusive Agreement for NATESTO(TM) ...

TORONTO, ONTARIO -- (Marketwired) -- 12/09/14 -- Trimel Pharmaceuticals Corporation (TSX: TRL) today announced the closing of the previously communicated agreement between its subsidiary, Trimel BioPharma SRL, and an affiliate of Endo International ...

Trimel Announces Issuance of Additional Patent Covering NATESTO(TM) ...

TORONTO, ONTARIO -- (Marketwired) -- 11/25/14 -- Trimel Pharmaceuticals Corporation (TSX: TRL) today announced that its technology partner Mattern Pharma AG has been granted an additional United States Patent in respect of NATESTO™ and its propri ...

Alle Meldungen von Trimel Pharmaceuticals Corporation